Discovery of ((4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-enyl)-3- (trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 49, Issue 22, 2006, Pages 6439-6442

  Pei, Zhonghua ^a   Li, Xiaofeng ^a   Von Geldern, Thomas W ^a   Madar, David J ^a   Longenecker, Kenton ^a   Yong, Hong ^a   Lubben, Thomas H ^a   Stewart, Kent D ^a   Zinker, Bradley A ^a   Backes, Bradley J ^a   Judd, Andrew S ^a   Mulhern, Mathew ^a   Ballaron, Stephen J ^a   Stashko, Michael A ^a   Mika, Amanda K ^a   Beno, David W A ^a   Reinhart, Glenn A ^a   Fryer, Ryan M ^a   Preusser, Lee C ^a   Kempf Grote, Anita J ^a   Sham, Hing L ^a   Trevillyan, James M ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[5 AMINO 4 (2,4,5 TRIFLUOROPHENYL)CYCLOHEX 1 ENYL][3 (TRIFLUOROMETHYL) 5,6 DIHYDRO 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7(8H) YL]METHANONE; ABT 341; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROCESS OPTIMIZATION; RAT; STRUCTURE ANALYSIS;

ANIMALS; ANTIGENS, CD26; BIPHENYL COMPOUNDS; CYCLOHEXENES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; RATS; RATS, ZUCKER; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; X-RAY DIFFRACTION;

EID: 33750456573     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060955d     Document Type: Article

References (40)

1. (a) Lambeir, A.-M.; Durnx, C.; Scharpe, S.; Meester, I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294.
2. (b) Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
3. (a) Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 15, 829-835.
4. (b) Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136, 3585-3596.
5. For reviews, see (c) Knudsen, L. B. Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 2004, 47, 4128-4134.
6. (d) Deacon, C. F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 2004, 36, 761-765.
7. (a) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A. M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secrection and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6874-6879.
8. (b) Conarello, S. L.; Li, Z.; Ronan, J.; Roy, R. S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6825-6830.
9. Nagakura, T.; Vasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fisher rats. Biochem. Biophys. Res. Commun. 2001, 284, 501-506.
10. (a) Reimer, M. K.; Holst, J. J.; Ahren, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 2002, 146, 717-727.
11. (b) Pospisilik, A.; Martin, J.; Doty, T.; Ehses, J. A.; Pamir, N.; Lynn, F. C.; Piteau, S.; Demuth, H.-U.; McIntosh, C. H. S.; Pederson, R. A. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52, 741-750.
12. (a) Ahrén, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-75.
13. (b) Ahrén, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
14. (c) Ahrén, B.; Landing-Olsson, L.; Jansson, P.-A.; Sevensson, M.; Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
15. (d) Ahrén, B.; Pacini, G.; Foley, J. E.; Schweizer, A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28, 1936-1940.
16. For reviews, see (a) Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 2004, 47, 4135-4141.
17. (b) Wiedeman, P. E.; Trevillyan, J. M. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr. Opin. Investig. Drugs 2003, 4, 412-420.
18. (c) Deacon, C. F.; Ahren, B.; Holst, J. Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes? Expert. Opin. Investig. Drugs 2004, 13, 1091-1102.
19. (d) Drucker, D. J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26, 2929-2940.
20. (e) Villhauer, E. B.; Coppola, G. M.; Hughes, T. E. DPPIV inhibition and therapeutic potential. Ann. Reports Med. Chem. 2001, 36, 191-200.;
21. (f) Gwaltney, S. L., II; Stafford, J. A. Inhibitors of Dipeptidyl Peptidase 4. Annu. Rep. Med. Chem. 2005, 40, 149-165.
22. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46, 2774-2789.
23. Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 5025-5037.
24. Mest, H.-J. Dipeptidyl peptidase-IV inhibition can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Curr. Opin. Invest. Drugs 2006, 7, 338-343.
25. Abbott, C. A.; Yu, D. M. T.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, expression, and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000, 267, 6140-6150.
26. Ajami, K.; Abbott, C. A.; McCaughan, G. W.; Gorrell, M. D. Dipeptidyl peptidase 9 has two forms, a broad tissue distrubution, cytoplasmic localization, and DPP-like peptidase activity. Biochem. Biophys. Acta 2004, 1679, 18-28.
27. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C.-C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, Z.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54, 2988-2994.
28. Larsen, J.; Hylleberg, B.; Ng, K.; Damsbo, P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24, 1416-1421.
29. Balas, B.; Baig, M.; Watson, C.; Dunning, B. E.; Ligueros-Saylan, M.; He, Y.-L.; Wang, B.; Cusi, K.; Foley, J. E.; Defranzo, R. A. Vildagliptin supresses endogenous glucose production (EGP) and increases beta cell function after single dose administration in type 2 diabetic (T2D) patients. American Diabetes Association 66th Scientific Session, Washington DC, 2006, 122-OR.
30. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Sinha, R. R.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)-butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 141-151.
31. Gwaltney, S. L.; Aertgeerts, K.; Feng, J.; Kaldor, S. W.; Kassel, D. B.; Manuel, M.; Navre, M.; Prasad, S. G.; Shi, L.; Skene, R. J.; Stafford, J. A.; Wallace, M.; Xu, R.; Ye, S.; Zhang, Z. Abstracts of Papers, 231st Meeting of the American Chemical Society, Atlanta, GA, 2006, MEDI-018.
32. Madar, D. J.; Kopecka, H.; Pireh, D.; Yong, H.; Pei, Z.; Li, X.; Wiedeman, P.; Djuric, S. W.; von Geldern, T. W.; Fickes, M.; Bhagavatula, L.; McDermott, T.; Wittenberger, S.; Longenecker, K.; Stewart, K.; Lubben, T. H.; Ballaron, S. J.; Stashko, M. A.; Long, M.; Wells, H.; Zinker, B. A.; Mika, A. K.; Beno, D. W. A.; Kempf-Grote, A. J.; Polakowski, J.; Segreti, J.; Reinhart, G. A.; Fryer, R.; Sham, H. L.; Trevilliyan, J. M. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino] -4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): A very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. J. Med. Chem. Published ASAP, Sept. 23, 2006.
33. For details of assay conditions, see: Pei, Z.; Li, X.; Longenecker, K.; von Geldern, T. W.; Wiederman, P. E.; Lubben, T. H.; Zinker B. A.; Stewart, K.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K. Beno, D. W. A.; Long, M.; Wells, H.; Kempf-Grote, A. J.; Madar D. J.; McDermott, T. S.; Bhagavatula, L.; Fickes, M. G.; Pireh, D. Solomon, L. R.; Lake, M. R.; Edalji, R.; Fry, E. H.; Sham, H. L. Trevilyan, J. M. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2- cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. J. Med. Chem. 2006, 49, 3520-3535.
34. For a recent example, see: (a) Knobloch, K.; Keller, M.; Eberbach, W. The synthesis of annulated azepin-3-one derivatives from 1,3,4-pentatrienyl nitrones by a heterocyclization-rearrangement sequence. Eur. J. Org. Chem. 2001, 3313-3332.
35. (b) For a review, see: Marson, C. M. Reactions of carbonyl compounds with (monohalo) methyleniminium salts (Vilsmeier reagents). Tetrahedron 1992, 48, 3695-3726.
36. Refined crystallographic coordinates for the structures of DPP4 complexed with 25 have been deposited in Protein Data Bank (www.rcsb.org) with entry code 2178.
37. See Supporting Information for details.
38. (a) Bruk, D.; Wedd, D.; Burlinson, B. Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry. Mutagenesis 1996, 11, 201-205.
39. (b) Ciaravino, V.; Suto, M. J.; Theiss, J. C. High capacity in vitro micronucleus assay for the assessment of chromosome damage: results with quinolone/napthyridone antibacterials. Mutat. Res. 1993, 298, 227-236. (24) http://www.cerep.fr.
40. Fryer, R. M.; Preusser, L. C.; Calzadilla, S. V.; Hu, Y.; Xu, H.; Marsh, K. C.; Cox, B. F.; Lin, C. T.; Gopalakrishnan, M.; Reinhart, G. A. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydro-thieno-[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: Hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J. Cardiovasc. Pharmacol. 2004, 44, 137-147.